TO THE EDITOR
Chimaeric fusion genes created by nonrandom chromosomal translocations are characteristic of childhood acute lymphoblastic (ALL) and myeloid (AML) leukaemias. Although the mechanisms leading to these chromosomal rearrangements are unclear, careful analysis of the primary genomic fusion sequence has suggested a number of possible mechanisms. These include, aberrant VDJ recombinase activity, topoisomerase II-mediated breakage followed by erroneous end joining, illegitimate recombination mediated by repetitive DNA sequences, proteins that bind to specific DNAbinding sites and errors in nonhomologous end joining (NHEJ) following double-stranded DNA breaks.
1 Using polymerase chain reaction (PCR) -based techniques on DNA extracted from neonatal Guthrie cards, belonging to children diagnosed with leukaemia, it has been possible to show that some of these fusions occur prenatally. Fusions detected to date include the MLL-AF4 fusion in infantile ALL; the TEL-AML1 in childhood ALL and the AML1-ETO and MLL-CALM in childhood AML. Analysis of cells obtained from normal cord blood have shown that TEL-AML1 and AML1-ETO fusions are detected in the normal population at birth at a frequency that is a 100 times higher than the incidence of corresponding leukaemia. 2 Thus, while the events leading to the formation of chimaeric fusion genes occur in utero, only a few develop clinically overt leukaemia at a later date in early childhood. This suggests that additional postnatal genetic hits are required in these preleukaemic cells. Murine models of TEL-AML1 and AML1-ETO support this hypothesis, as the transgenes are insufficient themselves to induce leukaemia. We extend these observations by identifying a child with AML carrying a prenatally acquired MLL-AF10 fusion.
A 24-month-old boy presented with an acute history of fever and parotid enlargement. He was found to have subcutaneous nodules, generalised lymphadenopathy, splenomegaly and pancytopenia. Histopathological examination of bone marrow (BM) aspirate, trephine, lymph node (LN) and skin nodule did not reveal any features of a malignancy. Symptoms and signs regressed spontaneously and the child was kept under observation. After 6 weeks, all symptoms and signs recurred. This time, the marrow was infiltrated with 70% FAB M5 myeloid blasts and the LN biopsy showed a heavy infiltrate of malignant myeloid cells. He was started on the Medical Research Council AML 12 Trial and went into remission after the first course of chemotherapy. After 18 months, he is alive and well.
Cytogenetic analyses of the lymph node sample obtained at initial presentation detected the presence of an abnormal clone 46,XY, dic(1;19)(q10;q13) in a background of morphologically normal cells. This clone was also seen in 1/100 cells obtained from the BM sample obtained at the same time. Presence of this abnormal clone was confirmed from both BM and LN samples when the child represented with florid disease. At this time, routine screening of the same metaphase spread using fluorescent in situ hybridisation (FISH) with a probe for the MLL gene (Vysis, Richmond, UK) revealed an insertion of MLL into 10p12 ( Figure 1a) . No structural chromosomal alterations involving 11q23 were detected by conventional Gbanding and this insertion could not be detected by the use of whole-chromosome 11 paint (Figure 1b ). The MLL and AF10 genes are oriented in the opposite direction on their respective chromosomes. 3 Thus, complex chromosomal rearrangements, requiring at least three breaks are required for an in-frame 5 0 MLL-3 0 AF10 fusion to occur. 4 Although these rearrangements are usually visible at the cytogenetic level, as is illustrated by this case, they can occasionally be cryptic underlining the importance of using FISH in addition to G-banding to characterise leukaemia-associated cytogenetic changes.
We have previously described the t(10;11)(p12;q23) to result in an MLL-AF10 fusion. 5 RNA was extracted from diagnostic BM cells, and a nested reverse transcriptase polymerase chain reaction (RT-PCR) was performed to detect the MLL-AF10 fusion transcript as previously described. 6 First round PCR was carried out with MLL ex 5F and AF10 2376R followed by a nested reaction using MLL ex 6F and AF10 1147R (listed in Table 1 ). An amplified product of 244 bp was obtained and on sequencing confirmed an in-frame fusion of MLL exon 6 with AF10 (979 bp) (Figure 2a ). Precise determination of the genomic breakpoint was determined by long-range PCR, using GeneAmp, XL-PCR kit (PE Applied Biosystems, Foster City, USA), with specific 5 0 MLL and 3 0 AF10 intronic primers. High molecular weight DNA was extracted from marrow cells and LN obtained at diagnosis, and from the initial presentation BM slide for which no other sample was available. A single round of PCR was performed using MLL BP1F (intron 6 1102-1123) and AF10 BP1R (978/979 intron 11019-10997) and the products TA cloned and sequenced. The 21 kb of intronic sequence was screened by long-range PCR (data not shown) and the precise genomic breakpoint was localised to MLL intron 6 position 1512 and AF10 intron position 10884 (between coding sequences 978 and 979). Breakpoint-specific primers (MLL BP1F and AF10 BP1R) were then used to confirm the presence of this fusion in the LN DNA. A product of 536 bp was amplified and sequenced. DNA isolated from the original presentation BM slide and from segments of the Guthrie card were then screened for the presence of the genomic fusion using seminested PCR (MLL BP1F and AF10 BP1R followed by MLL BP2F and AF10BP1R). A PCR product of 172 bp was successfully amplified from DNA extracted from the BM slide and from three segments of Guthrie card. Sequence analysis confirmed the genomic fusions to be identical to that observed in the LN DNA. Analysis of the junctional breakpoint at a single-nucleotide level was carried out based on the draft genomic sequence analysis of human chromosome 11 (GenBank accession no. NT_033899) and chromosome 10 (GenBank accession no. NT_008705). There was a 3-bp insertion into the fusion sequence and the translocation also contained very short sequence homologies. These latter structures have been described for complex translocations including the formation of dicentric chromosomes in murine lymphoma models. 7 Further analysis of the introns involved in this fusion showed them to be highly repetitive. The MLL intron has previously been described to have four Alu repeats. This study shows that the breakpoint AF10 intron contains 72% repetitive elements, chiefly made up of Alu and LINE repeats. The translocation junction is immediately flanked by an AluJb repeat from the MLL intron and a LIMCa repeat from the AF10 intron (Figure 2b) . The occurrence of repetitive sequences at 'junctional hot spots' in chromosomal translocations has frequently been observed and it is possible that clustering of such motifs makes these regions unstable and highly plastic, increasing the likelihood for rearrangements to occur.
This study provides further evidence that gene fusions characteristic of childhood leukaemias may be generated in utero. A retrovirally transduced MLL-AF10 fusion, encoding a similar chimaeric product, is also capable of transforming and immortalising murine myeloid cells. 8 These MLL-AF10 transduced cells are leukaemogenic to syngeneic recipients after a latency of 60-100 days. Similar latency periods prior to development of leukaemia have been observed for other MLL and for AML1-ETO transgenics. These observations support the current understanding that secondary genomic changes occurring after the translocation are required for overt clinical disease to manifest. It is unclear as to what secondary genetic changes are required for disease to manifest after a cell has acquired an AML-related fusion gene. A number of secondary chromosomal aberrations have been described in MLL-AF10-associated AML. In this child, the only overt cytogenetic abnormality was a dic(1;19), which resulted in trisomy 1q. Gain of 1q is a well-described phenomenon in a wide range of malignant disease, including AML, and we have previously identified a trisomy 1q in a child with MLL-AF10. However, as it is not possible to ascertain whether the 1q abnormality was also present antenatally, we can only speculate on its role in leukaemogenesis. What is evident is that an increasing number of leukaemia-associated fusion genes will be shown to occur prenatally. These premalignant clones will provide useful tools in which to study specific secondary changes required for transformation.
In summary, we have described a child diagnosed to have AML FAB M5. G-banding identified a dic(1;19). Subsequent FISH analysis identified a cryptic insertion of MLL into 10p12 and a MLL-AF10 fusion confirmed using RT-PCR. Using long-range PCR, the precise genomic breakpoint was localised to repeat rich regions in both introns. An identical genomic fusion was identified from DNA extracted from the neonatal Guthrie blood spot. This is the first report of a MLL-AF10 fusion at birth and provides further evidence of the prenatal origin of chromosomal translocations seen in childhood acute leukaemias. 
